Drugs that contain Ganaxolone

1. List of Ztalmy drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8318714 MARINUS Liquid ganaxolone formulations and methods for the making and use thereof
Nov, 2026

(3 years from now)

US8618087 MARINUS Solid ganaxolone formulations and methods for the making and use thereof
Nov, 2026

(3 years from now)

US9056116 MARINUS Liquid ganaxolone formulations and methods for the making and use thereof
Nov, 2026

(3 years from now)

US8367651 MARINUS Solid ganaxolone formulations and methods for the making and use thereof
Nov, 2026

(3 years from now)

US9029355 MARINUS Solid ganaxolone compositions and methods for the making and use thereof
Nov, 2026

(3 years from now)

US8022054 MARINUS Liquid ganaxolone formulations and methods for the making and use thereof
Nov, 2026

(3 years from now)

US7858609 MARINUS Solid ganaxolone formulations and methods for the making and use thereof
Nov, 2026

(3 years from now)

US10603308 MARINUS Methods and compositions for treatment of epileptic disorders
Aug, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 1, 2027
Orphan Drug Exclusivity (ODE) Jun 1, 2029

NCE-1 date: 2026-06-01

Market Authorisation Date: 01 June, 2022

Treatment: Treatment of seizures associated with cyclin-dependent kinase-like 5 (cdkl5) deficiency disorder (cdd) in patients 2 years of age and older

Dosage: SUSPENSION;ORAL

More Information on Dosage

ZTALMY family patents

28

United States

4

Korea, Republic of

4

Japan

3

Mexico

3

China

3

European Union

2

Israel

2

Australia

2

Canada

1

Colombia

1

New Zealand

1

AP

1

EA

1

Spain

1

Brazil

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic